YuanYi Bio Completes Nearly RMB 100 Million Series A Funding to Accelerate R&D and Production of Novel Synthetic Biology Products
VCBeat has learned that Yuanyi (Tianjin) Biotechnology Co., Ltd. (hereinafter referred to as “Yuanyi Bio”) has completed a financing round led byTasly, Xi'an Ruipeng AssetsLed the nearly RMB 100 million Series A financing round. The funds raised will be used for the research and development of new products, capacity expansion of existing products, and market promotion.
Yuan Yi Bio, centered on its leading synthetic biology technologies and guided by an “engineering” mindset, has developed high-efficiency gene-editing tools, designed innovative genetic metabolic pathways, and built highly productive cell factories, offering services that includeOne-Stop Solution: Engineered Strain Development – Fermentation Process Optimization – Industrial Fermentation Production – Product Separation and Purification – End-Product Development
Furthermore, the company boasts some of China’s earliest top-tier technical experts and industrialization talents in the field of synthetic biology. These individuals have not only led or participated in numerous national high-tech research and development programs, key national R&D initiatives in synthetic biology, and projects funded by the National Natural Science Foundation of China, but have also published multiple high-quality papers in prestigious scientific journals such as Science and Nature subsidiary journals, while demonstrating outstanding capabilities in commercialization.
Through the years of effort by its R&D team, the company hasTargeting biopharmaceutical CROs, functional ingredients for medical aesthetics/skincare, economic animal and plant nutrition, nutritional health supplements, healthy food ingredients, and new biotechnologiesand other application areas, completing theAstaxanthinandSuperoxide Dismutasea diversified product pipeline layout represented by...
Yuanyi Biotech's Astaxanthin ProductsHigh content, strong antioxidant activity, easy absorption, high temperature resistance (retention rate >90% after processing at 120°C for 30 min), and strong stability; rich in nutrients such as yeast extract and carotenoids; cost-effective and highly recognized by numerous users.
Another High-Value-Added Product of the CompanySuperoxide Dismutase, with mature commercialization potential. Superoxide dismutase (SOD) produced via traditional plant and animal extraction methods carries a risk of cross-contamination, incurs high production costs, and exhibits poor stability; it rapidly loses activity when exposed to environmental factors such as temperature fluctuations. Leveraging extensive expertise in enzyme evolution, Yuan Yi Biotechnology has addressed the industry-wide challenge of low SOD activity, significantly enhancing both enzymatic activity and stability while improving production efficiency. Currently commercially available SOD can withstand temperatures up to 100°C, with an enzymatic activity reaching 80,000 U/mg.
The company has proactively entered the end-user skincare market, incubating its proprietary skincare brand, Yuancolor. Its flagship product, the Hydrating Skin-Rejuvenating Serum, is rich in highly active superoxide dismutase (SOD), which effectively scavenges free radicals and provides skin-friendly moisturization and care. Formulated with sodium hyaluronate, tremella fuciformis polysaccharides, and bifida ferment lysate, the serum delivers multi-pathway, layered hydration and high-efficiency synergy, establishing a three-dimensional “point-line-surface” moisturizing and protective system. The Yuancolor serum is currently on the market, with additional products in the series to be launched sequentially.
Yuanyi Biologics has long focused on CRO services for peptide-based biologics. Unlike E. coli-based peptide production platforms, which suffer from drawbacks such as high levels of contaminating proteins and elevated purification costs, Yuanyi Biologics’ platform is built on an excretory Saccharomyces cerevisiae chassis cell system. It employs an inorganic salt culture medium in the extracellular environment, eliminating the need for purification, achieving high production efficiency, and attaining gram-per-liter (g/L) expression levels. Recently, the company has completed phased deliverables for a leading pharmaceutical company.
Leveraging its robust technical capabilities and the superior performance metrics of its diverse product portfolio, the company has also garnered favor from industry stakeholders. Across multiple sectors—including pharmaceuticals, agriculture, and general health—the company has established diversified collaborative models with major enterprises such as Sinopharm Taiji and Xiangyu Group to pursue mutual development. In the pharmaceutical sector, it is injecting new vitality into industry growth by leveraging technical services and patent licensing as key drivers.
The agricultural inputs business segment is also maturing, having established collaborations with dozens of large-scale agricultural companies to gradually form a cluster of high-quality products. In the animal health sector, the company has actively cooperated with more than 30 partners, including China’s leading feed enterprises, flagship specialized aquatic feed manufacturers, and premier premix producers, to conduct multi-species trials on shrimp, laying hens, and other animals, achieving satisfactory results. Meanwhile, the company has reached cooperation intentions with well-known enterprises in the medical aesthetics industry for raw material supply, joint development, and customized skincare products. Looking ahead, it will empower product upgrades and jointly build a new pattern of development.
Dr. Li Zhang, Founder of Yuanyi BiotechStatement: We extend our sincere gratitude to the investors for their trust and support. Leveraging this financing, the Company will continue to enhance its R&D capabilities, accelerate the commercialization of multiple research achievements, and drive industrial transformation and upgrading. Meanwhile, we will actively build a global marketing system to boost brand awareness, striving to establish the Company as a world-leading synthetic biology industry platform. We aim to provide partners across various sectors with a comprehensive suite of services—including custom engineered strains, patent licensing, raw material supply, joint development, product customization, and independent brand innovation—thereby fostering long-term, comprehensive, and deep strategic partnerships that deliver mutual benefits and shared success.
Tasly Capital
Leveraging the brand strength and industrial empowerment of Tasly Group, Tasly Capital’s team boasts extensive industry background and medical resources. Since its establishment, the firm has managed hundreds of billions in capital, investing in high-quality projects across all stages of the entire healthcare value chain, including pharmaceuticals, medical devices, healthcare services, and digital health. Additionally, it provides portfolio companies with advisory services in strategy, corporate governance, organizational development, finance, human resources, and marketing, fostering mutual growth alongside these enterprises.
Xi'an Ruipeng Asset
Xi'an Ruipeng Asset Management Co., Ltd. is a professional asset management and investment institution specializing in niche sectors of national core technological assets, including the military industry, new energy, and critical technologies subject to foreign restrictions ("chokehold" projects). The management platforms and funds under Xi'an Ruipeng have aggregated resources from national, provincial, municipal, and district-level investment platforms, as well as renowned state-owned enterprises and leading private firms such as InnoCapital, Shaanxi Investment Group Fund (a provincial comprehensive fund management platform), Qujiang Cultural Investment Group, Shaanxi Financial Holding Group, and the Xi'an Yanliang Aviation Base. The company manages assets exceeding RMB 2 billion. Xi'an Ruipeng has led investments in more than 30 companies and made direct Series A investments in dozens of others, with over ten of these portfolio companies having become leaders in their respective niches, either achieving IPOs or currently in the application process.